VAHDAM targets ₹100 Cr India run rate by FY27, ₹1,000 Cr wellness business by FY29

After building its tea business internationally, VAHDAM is accelerating its India D2C push across teas, supplements and functional botanical products. The brand says its India business reached a ₹30–35 Cr annual run rate within three months of formal launch and grew 2.5X year on year.

— Source publishedThu, 23 Jul, 2026, 09:47 IST·First seen Thu, 23 Jul, 2026, 18:20 IST·Source Inc42

What happened

VAHDAM is prioritising India after a decade of global expansion, targeting a ₹100 Cr domestic annual run rate by FY27 and a profitable ₹1,000 Cr wellness

Key facts

  • ₹350 Cr FY26 revenue
  • ₹500 Cr+ FY27 revenue target
  • ₹100 Cr India annual run-rate target by end-FY27
  • ₹1,000 Cr profitable wellness-business target by FY29
  • India business grew 2.5X year-on-year
  • India crossed ₹30-35 Cr annual run rate within three months of formal launch
  • 95-96% of revenue previously came from international markets
  • Products sold in 180+ countries
  • 250+ SKUs
  • 1,25,000 sq ft processing and packaging facility
  • FY23 bottom-line impact of nearly ₹35 Cr
  • FY21 revenue of around ₹160 Cr
  • Wellness teas and herbal infusions account for nearly 70% of tea business

Why this matters

VAHDAM’s wellness ambition creates partnership or acquisition opportunities in supplements, functional botanicals, clinical validation, and offline distribution to accelerate scale beyond tea.

What to watch

  • Quarterly India run-rate progression toward ₹50 Cr and then ₹100 Cr by FY27.
  • Share of India revenue from supplements and functional botanicals versus core tea.
  • Repeat-purchase rate, subscription penetration, customer-acquisition cost and contribution margin for Indian D2C orders.
  • Availability and ranking on Amazon, Nykaa, Tata 1mg, Blinkit, Zepto and other relevant channels.
  • New funding, senior wellness-category hires, manufacturing capacity additions or major retail distribution partnerships.
  • Evidence of claims compliance, third-party testing, clinical validation and any regulatory action affecting supplements or botanicals.
  • Whether international tea demand continues funding India acquisition and product-development investment.
  • Increase India performance marketing, creator partnerships and sampling to convert existing tea awareness into D2C acquisition.
  • Build replenishment and subscription programs around daily-use tea, sleep, immunity, gut-health and energy routines.
  • Use tea bundles as an entry point for functional botanical and supplement trial, raising average order value without relying solely on discounts.
  • Expand selectively into marketplaces, quick commerce and premium offline retail while preserving D2C customer-data ownership.
  • Invest in clinical substantiation, transparent ingredient sourcing and compliant wellness claims to build supplement-category trust.
  • Localize pack sizes and price points to widen access beyond affluent metro consumers while protecting premium positioning.

Also reported by